Abstract
Introduction: Multiple myeloma (MM) is uncommon in persons younger than 50 years of age. The presenting features in this age group are unclear. Methods: We analyzed a cohort of patients <50 years of age with MM treated in our center. Results: Twenty-three patients at a median age of 41.5 years (range 27–49) were analyzed. Patients presented at International Staging System (ISS) I–II (79%), had high frequency of bone lytic lesions (89%), extramedullary disease (26%), light-chain myeloma (45%), and translocation t(11;14) (68%). The subpopulation of patients carrying t(11;14) were younger (p = 0.025). This subgroup had higher bone marrow infiltration of plasma cells (75 vs. 47.5%), higher incidence of proteinuria (2.9 vs. 0.19 g/day), and poorer response to therapy: 85.7% of patients achieving complete/very good partial remission after induction therapy did not have t(11;14). A trend toward inferior progression-free survival (PFS) was observed in patients with t(11; 14) compared to patients without this translocation (median PFS 18 and 36 months, respectively). Discussion/Conclusion: Translocation t(11; 14) seems to be more prevalent in young myeloma patients. Young myeloma patients and especially those who harbor translocation t(11; 14) may represent a distinct clinical entity that confers a poor outcome.
References
1.
Raab
MS
, Podar
K
, Breitkreutz
I
, Richardson
PG
, Anderson
KC
. Multiple myeloma
. Lancet
. 2009
Jul
;374
(9686
):324
–39
.
[PubMed]
0140-67362.
Weiss
BM
, Abadie
J
, Verma
P
, Howard
RS
, Kuehl
WM
. A monoclonal gammopathy precedes multiple myeloma in most patients
. Blood
. 2009
May
;113
(22
):5418
–22
.
[PubMed]
0006-49713.
Kyle
RA
, Gertz
MA
, Witzig
TE
, Lust
JA
, Lacy
MQ
, Dispenzieri
A
, et al. Review of 1027 patients with newly diagnosed multiple myeloma
. Mayo Clin Proc
. 2003
Jan
;78
(1
):21
–33
.
[PubMed]
0025-61964.
Kyle
RA
, Therneau
TM
, Rajkumar
SV
, Offord
JR
, Larson
DR
, Plevak
MF
, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance
. N Engl J Med
. 2002
Feb
;346
(8
):564
–9
.
[PubMed]
0028-47935.
Kyle
RA
, Therneau
TM
, Rajkumar
SV
, Larson
DR
, Plevak
MF
, Offord
JR
, et al. Prevalence of monoclonal gammopathy of undetermined significance
. N Engl J Med
. 2006
Mar
;354
(13
):1362
–9
.
[PubMed]
0028-47936.
Rajkumar
SV
, Landgren
O
, Mateos
MV
. Smoldering multiple myeloma
. Blood
. 2015
May
;125
(20
):3069
–75
.
[PubMed]
0006-49717.
Rajkumar
SV
, Gupta
V
, Fonseca
R
, Dispenzieri
A
, Gonsalves
WI
, Larson
D
, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
. Leukemia
. 2013
Aug
;27
(8
):1738
–44
.
[PubMed]
0887-69248.
Neben
K
, Jauch
A
, Hielscher
T
, Hillengass
J
, Lehners
N
, Seckinger
A
, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load
. J Clin Oncol
. 2013
Dec
;31
(34
):4325
–32
.
[PubMed]
0732-183X9.
Corso
A
, Klersy
C
, Lazzarino
M
, Bernasconi
C
. Multiple myeloma in younger patients: the role of age as prognostic factor
. Ann Hematol
. 1998
Feb
;76
(2
):67
–72
.
[PubMed]
0939-555510.
Bladé
J
, Kyle
RA
, Greipp
PR
. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years
. Br J Haematol
. 1996
May
;93
(2
):345
–51
.
[PubMed]
0007-104811.
Ludwig
H
, Durie
BG
, Bolejack
V
, Turesson
I
, Kyle
RA
, Blade
J
, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
. Blood
. 2008
Apr
;111
(8
):4039
–47
.
[PubMed]
0006-497112.
Rajkumar
SV
, Dimopoulos
MA
, Palumbo
A
, Blade
J
, Merlini
G
, Mateos
MV
, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
. Lancet Oncol
. 2014
Nov
;15
(12
):e538
–48
.
[PubMed]
1470-204513.
Greipp
PR
, San Miguel
J
, Durie
BG
, Crowley
JJ
, Barlogie
B
, Bladé
J
, et al. International staging system for multiple myeloma
. J Clin Oncol
. 2005
May
;23
(15
):3412
–20
.
[PubMed]
0732-183X14.
Shimoni
A
, Nagler
A
, Kaplinsky
C
, Reichart
M
, Avigdor
A
, Hardan
I
, et al. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis
. Leukemia
. 2002
Aug
;16
(8
):1413
–8
.
[PubMed]
0887-692415.
Trakhtenbrot
L
, Hardan
I
, Koren-Michowitz
M
, Oren
S
, Yshoev
G
, Rechavi
G
, et al. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma
. Genes Chromosom Cancer
; 2010
. 16.
Durie
BG
, Harousseau
JL
, Miguel
JS
, Bladé
J
, Barlogie
B
, Anderson
K
, et al.; International Myeloma Working Group
. International uniform response criteria for multiple myeloma
. Leukemia
. 2006
Sep
;20
(9
):1467
–73
.
[PubMed]
0887-692417.
Hansford
BG
, Silbermann
R
. Advanced Imaging of Multiple Myeloma Bone Disease
. Front Endocrinol (Lausanne)
. 2018
Aug
;9
:436
.
[PubMed]
1664-239218.
Bladé
J
, Fernández de Larrea
C
, Rosiñol
L
, Cibeira
MT
, Jiménez
R
, Powles
R
. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach
. J Clin Oncol
. 2011
Oct
;29
(28
):3805
–12
.
[PubMed]
0732-183X19.
Rafae
A
, Malik
MN
, Abu Zar
M
, Durer
S
, Durer
C
. An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring
. Cureus
. 2018
Aug
;10
(8
):e3148
.
[PubMed]
2168-818420.
Landgren
O
, Kyle
RA
, Pfeiffer
RM
, Katzmann
JA
, Caporaso
NE
, Hayes
RB
, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
. Blood
. 2009
May
;113
(22
):5412
–7
.
[PubMed]
0006-497121.
Avet-Loiseau
H
, Attal
M
, Moreau
P
, Charbonnel
C
, Garban
F
, Hulin
C
, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
. Blood
. 2007
Apr
;109
(8
):3489
–95
.
[PubMed]
0006-497122.
Fonseca
R
, Blood
EA
, Oken
MM
, Kyle
RA
, Dewald
GW
, Bailey
RJ
, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
. Blood
. 2002
May
;99
(10
):3735
–41
.
[PubMed]
0006-497123.
Leiba
M
, Duek
A
, Amariglio
N
, Avigdor
A
, Benyamini
N
, Hardan
I
, et al. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
Genes Chromosom Cancer
; 2016
. 24.
Bochtler
T
, Hegenbart
U
, Kunz
C
, Granzow
M
, Benner
A
, Seckinger
A
, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens
. J Clin Oncol
. 2015
Apr
;33
(12
):1371
–8
.
[PubMed]
0732-183X25.
Pawlyn
C
, Melchor
L
, Murison
A
, Wardell
CP
, Brioli
A
, Boyle
EM
, et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
. Blood
. 2015
Jan
;125
(5
):831
–40
.
[PubMed]
0006-497126.
Lakshman
A
, Alhaj Moustafa
M
, Rajkumar
SV
, Dispenzieri
A
, Gertz
MA
, Buadi
FK
, et al. Natural history of t(11;14) multiple myeloma
. Leukemia
. 2018
Jan
;32
(1
):131
–8
.
[PubMed]
0887-692427.
Kumar
S
, Kaufman
JL
, Gasparetto
C
, Mikhael
J
, Vij
R
, Pegourie
B
, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
. Blood
. 2017
Nov
;130
(22
):2401
–9
.
[PubMed]
0006-497128.
Matulis
SM
, Gupta
VA
, Nooka
AK
, Hollen
HV
, Kaufman
JL
, Lonial
S
, et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
. Leukemia
. 2016
May
;30
(5
):1086
–93
.
[PubMed]
0887-692429.
Punnoose
EA
, Leverson
JD
, Peale
F
, Boghaert
ER
, Belmont
LD
, Tan
N
, et al. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
. Mol Cancer Ther
. 2016
May
;15
(5
):1132
–44
.
[PubMed]
1535-716330.
Moreau
P
, Chanan-Khan
A
, Roberts
AW
, Agarwal
AB
, Facon
T
, Kumar
S
, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
. Blood
. 2017
Nov
;130
(22
):2392
–400
.
[PubMed]
0006-497131.
Leverson
JD
, Sampath
D
, Souers
AJ
, Rosenberg
SH
, Fairbrother
WJ
, Amiot
M
, et al. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
. Cancer Discov
. 2017
Dec
;7
(12
):1376
–93
.
[PubMed]
2159-827432.
Touzeau
C
, Le Gouill
S
, Mahé
B
, Boudreault
JS
, Gastinne
T
, Blin
N
, et al. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)
. Haematologica
. 2017
Mar
;102
(3
):e112
–4
.
[PubMed]
0390-607833.
Billecke
L
, Murga Penas
EM
, May
AM
, Engelhardt
M
, Nagler
A
, Leiba
M
, et al. Cytogenetics of extramedullary manifestations in multiple myeloma
. Br J Haematol
. 2013
Apr
;161
(1
):87
–94
.
[PubMed]
0007-1048© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
